Navigation Links
New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses
Date:3/14/2012

PARSIPPANY, New Jersey, March 14, 2012 /PRNewswire/ --

Ingenol mebutate was proven efficacious with a once-daily application for only 2 or 3 days

Today, the New England Journal of Medicine (NEJM) published an analysis of pooled results from LEO Pharma's four Phase III clinical trials for ingenol mebutate gel, demonstrating that ingenol mebutate gel is safe and effective for the treatment of actinic keratoses (AKs) on the trunk-extremities or face-scalp with only 2 or 3 days use, respectively.[1]

     (Logo: http://www.newscom.com/cgi-bin/prnh/20110606/460992)

Ingenol mebutate gel, marketed in the US as Picato®, is a new topical gel for the treatment of actinic keratosis. Actinic keratoses can be considered a precursor to squamous cell carcinoma (SCC).[3]The authors of this publication concluded that with a once-daily treatment for only 2 or 3 consecutive days, ingenol mebutate gel will provide physicians with an effective new option for the treatment of actinic keratosis.

The authors of the article, Ingenol Mebutate Gel for Actinic Keratosis, reported, "Two clear benefits are derived from the short exposure to ingenol mebutate."  The article explains that the short 2- or 3-day dosing combined with the rapid resolution of local skin responses (LSRs) may benefit patients.    

Lead author Mark Lebwohl, M.D., Professor and Chair, Department of Dermatology, Mount Sinai Medical Center in New York, said: "In these Phase III trials, almost all patients completed the full course of treatment. The evidence provided by these controlled studies shows ingenol mebutate gel to be an effective treatment for AKs on the head or body."

Ingenol mebutate gel is a field-directed topical therapy that enables treatment of an area or field containing AKs on the head or body. In the pooled analysis of the face and scalp data in the New England Journal of M
'/>"/>

SOURCE LEO Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
2. Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
3. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
4. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
5. Fuse Science Partners With the New England Consulting Group to Advance Technology Licensing Efforts in Pharmaceutical and OTC Categories
6. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
7. NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner
8. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
9. New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands
10. River Valley Community College and Medical Messenger Team Up to Prepare the Future Nurses of New England
11. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe ... Hartley , Managing Partner and Healthcare Industry Group Leader, ... 100, which recognizes the most inspiring people in the ... leaders in research and development, marketing, technology, creativity, strategy ... in 2006 as a partner in its leading Rosetta ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), reported ... announced the selection of its,disinfectant, EnviroTru(TM) for ... (Metro). EnviroTru(TM) is a multi-purpose disinfectant ... also meets EPA requirements for,Toxicity Category IV ...
... of statins treated for 3 months with 200 mg/week mipomersen experienced ... continues to support mipomersen,s ... safety profile,- Isis hosting Analyst & Investor Day today - webcast live at 9:00 ... at http://www.isispharm.com , ...
Cached Medicine Technology:Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 2Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 4Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 5Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 6Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 7
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Restore ... Sen and Dr. Samantha Pearson to help people discover ... avoid corrective vision surgery by instead improving their eyesight ... an investigative review. , “There’s a reason why ... in revenue each year—it’s because people just assume that ...
(Date:8/22/2014)... August 22, 2014 CarePoint Health ... in Internal Medicine, Geriatrics, Hospice and Palliative Care, ... Health Medical Group. Their system welcomes Dr. Reisner ... experienced physicians comprise CarePoint Health Medical Group, a ... Hudson County, representing a wide range of specialties. ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a historic ... $141 million campus renewal. Renderings of the ... the public. , The new patient tower is part ... campus that meets the needs of patients, families and care ... embody Dayton Children’s unique patient care mission and offer places ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... be, presented at 59th Annual Meeting of the American Association for the ... ... Oct. 31 ,Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.,(Nasdaq: ONXX ... 59th Annual Meeting of the American Association for the Study,of Live Diseases ...
... CHAPEL HILL, N.C., Oct. 31 Survival nurtures ... rely on their,customers, and employees, innovations in marketing, ... market share., Network with and learn from ... Annual Customer Experience Conference:,Integrated Customer Strategies that Enable ...
... a coma, 6 year chronic sciatica back pain, 15- and ... all these conditions were overcome using advanced magnetic therapy techniques ... ... Pennsylvania (PRWEB) October 31, 2008 -- Regenerating nerves, waking people ...
... published finds that, while about 40 percent of women ... that those issues are a source of significant personal ... Hospital (MGH) physician appears in the November issue of ... are common in women, but problems associated with personal ...
... Normal-weight women who carry out lots of vigorous exercise ... than those who don,t exercise vigorously. A study of ... BioMed Central,s open access journal Breast Cancer Research, ... a risk factor for the disease even in ...
... Nanoparticles Present in 4 out of 5,Sunscreens, Even ... N.Y., Oct. 30 Consumers Union,nonprofit publisher of ... 4 out of 5 sunscreens that claimed not ... urged the FDA to,require a full safety assessment, ...
Cached Medicine News:Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 2Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 3Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 4Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 5Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 6Health News:Survive the Economic Downturn Through Innovations in Integrated Customer Strategies 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 3Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 4Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 5Health News:While prevalent, sexual problems in women not always associated with distress 2Health News:Vigorous activity protects against breast cancer 2Health News:Consumers Union Urges FDA to Conduct Full Scale Safety Review of Nanoparticles in Sunscreen 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: